What’s happening in the brain in major depressive disorder?

Many different combinations of symptoms lead to a diagnosis of depression, and the many different subtypes and symptoms of depression are produced by molecular, cellular, and network interactions in the brain. An overview of current understanding of these interactions was presented at ECNP 2021 by Professor Gitte Moos Knudsen, Copenhagen, Denmark.

Changes in the brain linked to major depressive disorder

 

Major depressive disorder is a heterogeneous disease with many combinations of symptoms

Although major depressive disorder (MDD) is often thought about as one disease, it is clear there are many subtypes, said Professor Knudsen, who highlighted current understanding of the variety of biological mechanisms linked to MDD, including:

  • Altered neurotransmission involving the monoamines and the glutaminergic and GABAergic systems. The monoamine theory for MDD based on a lack of serotonin and to some extent noradrenaline has prevailed many years, said Professor Knudsen, but now the glutamatergic and GABAergic systems are also considered to play an important role.1

Altered neurotransmission in major depressive disorder involves the monoaminergic, glutamatergic, and GABAergic systems

  • The stress response involving the hypothalamic-pituitary-adrenal axis and neurosteroids, with changes in neuroactive steroid signaling particularly affecting the GABAergic system.1,2
  • Impaired neuroplasticity. Normally the brain adapts to what it learns leading to changes in the brain associated with increased synapses or production of new neurons in the hippocampal area, but this behavior is impaired in MDD.1
  • Neuroinflammation1

The default mode network plays a role in major depressive disorder

In addition, different brain regions interact to form a neural network providing connectivity between different brain regions, said Professor Knudsen. Some of these networks play a role in MDD, for example the default mode network.3

Anatomic changes in the brain in MDD include:

  • Impaired neuroplasticity and neurogenesis, glial-cell mediated damage and neuroinflammation microscopically. Impaired neuroplasticity and neurogenesis are evident on molecular imaging as decreased synaptogenesis1
  • A variety of gray and white matter changes, most notably hippocampal atrophy, macroscopically1

Hippocampal atrophy is a notable anatomic change in major depressive disorder

 

Impaired adaptive signaling results in the core symptoms of major depressive disorder

A video was played during Professor Knudsen’s presentation to explain adaptive signaling in the interconnected neuronal networks in the brain. Adaptive signaling allows the brain to respond and adapt to stimuli, seeking to restore homeostasis through excitatory, inhibitory, and modulatory signaling.3

  • GABA and glutamate are the primary inhibitory and excitatory neurotransmitters, respectively
  • The less prevalent monoaminergic neurons are modulatory

The GABA/glutamate balance is critical for all neuronal network functions including regulation of monoaminergic pathways.

The GABA/glutamate balance regulates monoaminergic pathways

Professor Knudsen explained that impaired adaptive signaling (i.e. impaired ability for the brain to respond and adapt to stimuli):

  • Is associated with altered neurotransmission and changes in neuroactive steroid signaling4
  • Results in dysregulation of neuronal networks,5 which in turn are linked to the core symptoms of major depressive disorder (MDD) — depressed mood, anhedonia, feelings of worthlessness or excessive guilt, suicidality, and sleep difficulties6  

 The core symptoms of major depressive disorder are linked to impaired adaptive signaling

Professor Knudsen highlighted that in the future the identification of biomarkers involved in these mechanisms will enable patient stratification into different subtypes and facilitate a precision medicine approach with more individualized treatment.

 

Educational financial support for this symposium was provided by Sage Therapeutics and Biogen.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References
  1. Otte C, et al. Major depressive disorder. Nat Rev Dis Primers 2016;2:16065.
  2. Duman RS, et al. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 2019;102(1):75–90.
  3. Yan C-G, et al. Reduced default mode network functional connectivity in patients with recurrent major depressive disorder. PNAS 2019;116(18):9078–83.
  4. Fogaça MV, Duman RS. Cortical GABAergic dysfunction in stress and depression: new insights for therapeutic interventions. Front Cell Neurosci. 2019;13:87.
  5. Lener MS, et al. Glutamate and GABA systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2017;81(10):886–97.
  6. Tolentino JC, Schmidt SL. DSM-5 criteria and depression severity: implications for clinical practice. Front Psych 2018;9:450.
You are leaving Progress in Mind

You are leaving

Progress in Mind Portugal
HCP Access verification required
To gain access, please provide details to verify you are a healthcare professional.
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
Congress
Register for access to Progress in Mind in your country